Aminoglycosides Market Size, Share & Trends Analysis Report By Product (Neomycin, Tobramycin, Gentamicin), By Route Of Administration (Injectables, Feed, Intra-mammary), By Application (Veterinary, Skin Infection), By Region, And Segment Forecasts, 2025 - 2035
Published Date: May - 2025 | Publisher: MIR | No of Pages: 239 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2999 Download Sample Ask for Discount Request CustomizationAminoglycosides Market Size and Forecast 2025 to 2034
The global aminoglycosides market size was estimated at USD 7.1 billion in 2024 and is predicted to increase from USD 7.55 billion in 2025 to approximately USD 13.1 billion by 2034, expanding at a CAGR of 6.32% from 2025 to 2034. The growth of the market is driven by the increasing government funding in research and development activities aimed at infectious and bacterial diseases.
Download Sample Ask for Discount Request Customization
Aminoglycosides Market Key Takeaways
- Asia Pacific dominated the aminoglycosides market with the largest share of 36% in 2024.
- North America is expected to grow at a notable CAGR between 2025 and 2034.
- By product, the gentamicin segment held the dominant share of the market in 2024.
- By product, the tobramycin segment is expected to grow at a significant rate in the coming years.
- By route of administration, the injectable segment dominated the market in 2024.
- By route of administration, the oral segment is likely to grow at the fastest rate during the forecast period.
- By application, the respiratory diseases segment dominated the market in 2024.
- By application, the skin infection segment is anticipated to expand at the highest CAGR during the projection period.
Role of AI in Aminoglycosides Development
Artificial Intelligence AI transforms the process of infectious diseases being under control by speeding up the discovery of antibiotics. AI facilitates the discovery of novel aminoglycoside formulations. AI methods like deep learning and machine learning assist in the prediction of resistance, detection of pathogens, and drug discovery. AI tools based on AI optimize antibiotic stewardship and identify effective compounds such as antimicrobial peptides and small molecules. AI optimizes drug discovery processes by enhancing precision and quality control. It examines huge compound datasets to discover probable aminoglycoside candidates with high bacterial target affinity. Further, AI interprets patient data to forecast individual responses to aminoglycosides. This further lowers the risk of complications and improves patient outcomes.
Asia Pacific Aminoglycosides Market Size and Growth 2025 to 2034
The size of the Asia Pacific aminoglycosides market was shown to be USD 2.56 billion in 2024 and is anticipated to reach an estimate of about USD 4.78 billion by 2034, expanding at a CAGR of 6.44% from 2025 to 2034.
Asia Pacific led the market for aminoglycosides with the highest share in 2024. This is primarily attributed to the augmented healthcare research, enhanced drug manufacturing capabilities, and commercialization of new drugs. There is high occurrence of infectious diseases, including bacterial infections. This greatly enhanced the demand for aminoglycosides.
China and India are key drivers of the Asia Pacific aminoglycosides market. As the increasing number of infections of infectious diseases in China provides a high interest in the innovation of new aminoglycoside formulations, the rise in cases of infectious diseases is also increasing due to the poor air and water quality in India. The increased incidence of infectious diseases in animals also creates a demand for aminoglycosides.
North America is anticipated to register the highest growth rate in the forecast period. Market growth in the region primarily stems from a growing incidence of infectious diseases, such as bacterial infections, as a result of climatic changes and the spread of antibiotic-resistant bacteria. Growing awareness among individuals regarding infectious diseases and health campaigns drive market growth. The rising geriatric population and healthcare expenditure per capita also drive regional market growth.
The U.S. is a key contributor to the North American market. The nation has some of the most prominent pharmaceutical firms, which are concentrating on new drug discovery and development, opening up opportunities for the aminoglycosides market. The rise of antimicrobial resistance in the U.S. also favors market growth. Resistant germs causing infections are difficult and at times impossible to treat, which heightens the demand for aminoglycosides. In addition, the U.S. government is investing significantly in researching more contemporary treatments for a wide array of infectious diseases, thereby propelling the aminoglycosides market's growth.
Market Overview
Aminoglycosides is an antibiotic, which is applicable in the treatment of aerobic gram-negative bacilli infections. They are effective against different bacteria, including Mycobacterium tuberculosis and Staphylococci. The major healthcare application of aminoglycosides is for the management of infectious and bacterial diseases. It is also used in the treatment of acute and chronic intestinal amebiasis and as an adjunct for the treatment of hepatic coma and to treat complicated urinary tract infections. Aminoglycosides are more effective against quickly multiplying organisms, and they affect and eventually destroy bacteria through different mechanisms. They need only a short contact with bacteria to kill them. The aminoglycosides market is witnessing rapid growth due to the rising prevalence of drug-resistant bacteria. Moreover, the rising R&D activities aimed at the development of new formulations support market expansion.
Download Sample Ask for Discount Request Customization
Aminoglycosides Market Growth Factors
- The increased prevalence of multidrug-resistant bacterial infections led to renewed interest in aminoglycosides and efforts to develop advanced aminoglycosides. Aminoglycosides are potent, broad-spectrum antibiotics that act by inhibiting protein synthesis.
- Ongoing advances in drug delivery systems further support the growth of the market. Advanced drug delivery systems (DDSs) are formulated with enhanced properties like increased permeability, smaller particle size, enhanced solubility, efficacy, stability, and low toxicity. Advanced DDSs significantly improve the performance of the therapeutic agent.
- The growing demand for cost-effective and quality healthcare services and the increased awareness about infectious diseases boost the growth of the market.
Market Scope
| Report Coverage | Details |
| Market Size by 2034 | USD 13.1 Billion |
| Market Size in 2025 | USD 7.55 Billion |
| Market Size in 2024 | USD 7.1 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 6.32% |
| Dominated Region | Asia Pacific |
| Fastest Growing Market | North america |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Product, Route of Administration, Application and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Download Sample Ask for Discount Request Customization
Market Dynamics
Drivers
Emerging Infectious Diseases
The continuous expansion of the human population in the new geographical regions significantly increases close contact with animal species that may serve as hosts for infectious agents. This rising interaction, combined with the accelerating effect of the changing climate, has become a persistent catalyst in the emergence of infectious diseases. These diseases are caused by pathogenic microorganisms, like bacteria, viruses, parasites, or fungi, and can spread both directly and indirectly among human beings. This results in the increased demand for antimicrobial treatment, particularly aminoglycosides, which drives the growth of the market.
Restraint
Nephrotoxicity Challenges
Potential side effects associated with aminoglycosides hamper the growth of the aminoglycosides market. Aminoglycosides can induce nephrotoxicity, with an increase in serum creatinine and hypoosmolar urinary results developing after some days of the treatment. They are nephrotoxic due to a small but sizable proportion of the directed dose being retained in the epithelial cells lining the S1 and S2 segments of the proximal tubules after glomerular filtration.
Opportunity
Next-Generation Antibiotics
The widespread emergence of multidrug-resistant and communicable bacterial strains has created an urgent need for advanced antibiotic solutions, creating immense opportunities in the aminoglycosides market. The development of next-generation aminoglycoside antibiotics, such as plazomicin, is a breakthrough in combating highly resistant gram-negative pathogens. Plazomicin, a novel aminoglycoside, functions by binding to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis in a concentration-dependent manner. It demonstrates a broad spectrum of activity against aerobic bacteria. This innovation not only enhances treatment efficacy but also opens new avenues for drug manufacturers.
Product Insights
The gentamicin segment held the largest share of the aminoglycosides market in 2024. Gentamicin is used for the treatment of serious bacterial infections in various parts of the body. Gentamicin belongs to the class of medicines known as aminoglycoside antibiotics. It works by killing bacteria or preventing their growth. Gentamicin is an aminoglycoside antibiotic used to treat different types of bacterial infections, including endocarditis, bone infections, pneumonia, meningitis, pelvic inflammatory disease, urinary tract infections, and sepsis.
The tobramycin segment is expected to grow at a significant rate in the coming years. It has huge intrinsic activity against Pseudomonas aeruginosa and some gentamicin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa strains. It is effective for treating external infections of the eyelid and eye caused by susceptible organisms. Tobramycin is an effective antibiotic normally used in the treatment and management of different ocular and systemic infections.
Route of Administration Insights
The injectable drugs segment dominated the aminoglycosides market with the largest share in 2024. Injectable aminoglycosides deliver an immediate, quick-acting therapeutic effect, which is significant in emergent conditions like narcotic overdose or cardiac arrest. They are very helpful in enhancing therapeutic effects as they can be completely absorbed as compared to medications given by other routes. Moreover, injectable aminoglycosides have proven to be highly effective in managing bacterial infections due to their enhanced safety and efficacy.
The oral segment is likely to grow at the fastest rate during the forecast period. Oral administration of medication is a cost-effective and convenient way. The primary site of drug absorption is commonly the small intestine, and the bioavailability of the drug depends on the quantity of drug absorbed across the intestinal epithelium. The oral route is usually the safest and most affordable; it is the most often used route of administration. Oral formulations are beneficial over injectable formulations, such as ease of administration and reduced side effects, which is a major factor boosting their demand.
Application Insights
The respiratory diseases segment held the largest share of the aminoglycosides market in 2024. This is mainly due to the increased number of cases of respiratory infections. Aminoglycosides are beneficial mostly in infections involving aerobic, Gram-negative bacteria, like Enterobacter, Acinetobacter, and Pseudomonas, which cause respiratory infections. Aminoglycosides are effective against gram-negative bacteria, which are common causes of respiratory infections like bronchitis and pneumonia.
The skin infection segment is anticipated to expand at the highest CAGR during the projection period. The growth of the segment is attributed to the rising prevalence of bacterial skin infections. Aminoglycosides are effective against a range of skin infections depending on the particular type and severity of the infection and the individual’s circumstances. Common and effective skin infection antibiotics include cephalosporins, penicillin derivatives, trimethoprim-sulfamethoxazole, and clindamycin.
Aminoglycosides Market Players Companies
Download Sample Ask for Discount Request Customization
- Pfizer Inc.
- Merck & Co., Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries
- Cipla Limited
- Sun Pharmaceutical Industries
- Lupin Limited
- Aurobindo Pharma
- Fresenius Kabi
- Viatris Inc.
Recent Developments in the Market
- In February 2024, Cipla strengthens its fight against antimicrobial resistance by securing approval to introduce ZEMDRI injection in India. Plazomicin is a new intravenous (IV) aminoglycoside indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis.
- In March 2024, Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference.
Segments Covered in the Report
By Product
- Neomycin
- Tobramycin
- Gentamicin
- Amikacin
- Paromomycin
- Streptomycin
- Kanamycin
- Others
By Route of Administration
- Injectable
- Feed
- Intra-mammary
- Topical
- Oral
By Application
- Veterinary
- Skin Infection
- Respiratory diseases
- UTI & Pelvic Diseases
- Other diseases
By Region
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy